Skip to content

Clinical observation of ultrasound-guided suprainguinal fascia iliaca compartment block combined with sacral plexus block and combined spinal epidural block in older adults with intertrochanteric fractures

Clinical observation of ultrasound-guided suprainguinal fascia iliaca compartment block combined with sacral plexus block and combined spinal epidural block in older adults with intertrochanteric fractures

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052045
Enrollment
Unknown
Registered
2021-10-15
Start date
2021-10-18
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intertrochanteric fracyures in older adults

Interventions

Control group:Inject 0.5% isobaric bupivacaine 1.5-2ml into the subarachnoid space between L2, 3 or L3, 4, and indwelling the catheter epidural
Experimental group:For suprainguinal fascia iliaca compartment block combined with sacral plexus block, 30ml of 0.375% ropivacaine was injected, and for sacral plexus block, 20ml of 0.375% ropivacaine

Sponsors

Dalian Municipal Central Hospital Affiliated to Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged > 60 years, with intertrochanteric fractures; 2. ASA I-III; 3. The first operation of unilateral intertrochanteric fracture; 4. No nerve block analgesia was performed 24 hours before operation.

Exclusion criteria

Exclusion criteria: 1. Refuse to participate in the test; 2. Patients who cannot undergo nerve block or combined block anesthesia; 3. In addition to intertrochanteric fractures, there are other fractures; 4. Prosthesis fracture; 5. Bilateral fracture; 6. Recent stroke (within 1 month); 7. Coexisting active heart disease (unstable angina pectoris, recent myocardial infarction, decompensated heart failure, severe arrhythmia, severe valvular heart disease); 8. Complicated with severe lung diseases (acute respiratory failure, acute lung infection, acute asthma); 9. Patients with contraindications to the anesthesia methods or drugs implemented in this trial.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale/Score;Total norepinephrine IV(intravenous injection);Analgesic dosage 24 hours after operation;Pro-BNP(Brain Natriuretic Peptide);Bauer patient satisfaction questionnaire;hs-cTnT;

Secondary

MeasureTime frame
ADL (Activity of Daily Living Scale);Incidence of nausea;Incidence of vomiting;

Countries

China

Contacts

Public ContactBi Congjie

Dalian Municipal Central Hospital Affiliated to Dalian Medical University

bcj0411@126.com+86 13504251513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026